Silence Therapeutics Plc
| London Stock Exchange: SLN
Silence Therapeutics Plc is engaged in the discovery, development and delivery of targeted, systemic RNA interference therapeutics for the treatment of serious diseases. The company provides pharmaceutical research services and develops products utilizing the immune system to combat disease such as cancer and the prevention and treatment of tuberculosis. Its principal activity is researching and developing biotechnology products. The company operates its business through two segments: RNAi therapeutics and Immunotherapy. Silence Therapeutics was founded on November 18, 1994 and is headquartered in London, the United Kingdom.